Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Concerns sort of short term sort of not

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Dec 02, 2020 11:51am

163 Views

Post# 32018164

RE:Concerns sort of short term sort of not

Welcome Ogre !

I'm not a fan of R/S either - unless there is a gameplan.
Thinking we have ourselves a gameplan.
Will see.

Going to market for more capital ... maybe ... sure hope they don't yet.

Going to US market is a potential - a possibility. I'm going to guess it all depends on how/where negotiations are going.

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December